Department of Pharmaceutical Sciences, University of Milan, Milan, Italy.
School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.
Proteins. 2022 Feb;90(2):372-384. doi: 10.1002/prot.26227. Epub 2021 Sep 20.
Antibiotic resistance is a major threat to global public health. β-lactamases, which catalyze breakdown of β-lactam antibiotics, are a principal cause. Metallo β-lactamases (MBLs) represent a particular challenge because they hydrolyze almost all β-lactams and to date no MBL inhibitor has been approved for clinical use. Molecular simulations can aid drug discovery, for example, predicting inhibitor complexes, but empirical molecular mechanics (MM) methods often perform poorly for metalloproteins. Here we present a multiscale approach to model thiol inhibitor binding to IMP-1, a clinically important MBL containing two catalytic zinc ions, and predict the binding mode of a 2-mercaptomethyl thiazolidine (MMTZ) inhibitor. Inhibitors were first docked into the IMP-1 active site, testing different docking programs and scoring functions on multiple crystal structures. Complexes were then subjected to molecular dynamics (MD) simulations and subsequently refined through QM/MM optimization with a density functional theory (DFT) method, B3LYP/6-31G(d), increasing the accuracy of the method with successive steps. This workflow was tested on two IMP-1:MMTZ complexes, for which it reproduced crystallographically observed binding, and applied to predict the binding mode of a third MMTZ inhibitor for which a complex structure was crystallographically intractable. We also tested a 12-6-4 nonbonded interaction model in MD simulations and optimization with a SCC-DFTB QM/MM approach. The results show the limitations of empirical models for treating these systems and indicate the need for higher level calculations, for example, DFT/MM, for reliable structural predictions. This study demonstrates a reliable computational pipeline that can be applied to inhibitor design for MBLs and other zinc-metalloenzyme systems.
抗生素耐药性是全球公共卫生的主要威胁。β-内酰胺酶能催化β-内酰胺类抗生素的水解,是主要原因之一。金属β-内酰胺酶(MBLs)代表了一个特别的挑战,因为它们几乎能水解所有的β-内酰胺类抗生素,而且迄今为止还没有 MBL 抑制剂被批准用于临床。分子模拟可以辅助药物发现,例如,预测抑制剂复合物,但经验性的分子力学(MM)方法通常对金属蛋白酶的表现不佳。在这里,我们提出了一种多尺度方法来模拟硫醇抑制剂与 IMP-1 的结合,IMP-1 是一种含有两个催化锌离子的临床重要的 MBL,并预测了一种 2-巯基甲基噻唑烷(MMTZ)抑制剂的结合模式。首先将抑制剂对接进入 IMP-1 的活性部位,在多个晶体结构上测试不同的对接程序和评分函数。然后将复合物进行分子动力学(MD)模拟,随后通过密度泛函理论(DFT)方法 B3LYP/6-31G(d)进行 QM/MM 优化来进行细化,通过连续步骤提高方法的准确性。该工作流程在两个 IMP-1:MMTZ 复合物上进行了测试,该方法重现了晶体学观察到的结合,并且应用于预测第三个 MMTZ 抑制剂的结合模式,该抑制剂的复合物结构在晶体学上难以解决。我们还在 MD 模拟和 SCC-DFTB QM/MM 方法的优化中测试了一个 12-6-4 非键相互作用模型。结果表明,经验模型在处理这些系统时存在局限性,并表明需要更高水平的计算,例如 DFT/MM,以进行可靠的结构预测。这项研究展示了一种可靠的计算管道,可应用于 MBL 和其他锌金属酶系统的抑制剂设计。